Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

By Cavalli-Björkman Nina   Ösby Eva   Lundin Jeanette   Kalin Mats   Österborg Anders   Gruber Astrid  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 277-280

Humana Press, Inc

Access to resources Recommend Favorite

Alemtuzumab in chronic lymphocytic leukemia

By James Danelle F   Kipps Thomas J  

Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. : 29-42

Future Medicine

Access to resources Recommend Favorite

Eradication of Minimal Residual Disease with Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients: The Need for a Standard Method of Detection and the Potential Impact of Bone Marrow Clearance on Disease Outcome

By Montillo Marco   Schinkoethe Timo   Elter Thomas  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 488-496

Informa Healthcare

Access to resources Recommend Favorite

B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn

By Herishanu Yair  

Leukemia and Lymphoma, Vol. 54, Iss. 6, 2013-06 ,pp. : 1125-1126

Informa Healthcare

Access to resources Recommend Favorite

High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia’s High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 359-368

Humana Press, Inc

Access to resources Recommend Favorite